Pacira Q2 revenue slightly beats estimates; cuts FY outlook

Pacira BioSciences

04/08/2026 21:13

Overview
US non-opioid pain therapies maker's Q2 revenue rose 6%, slightly beating analyst expectations
Adjusted net income and adjusted EBITDA for Q2 both beat analyst estimates
Company completed divestiture of iovera° business to Zimmer Biomet in July

Outlook
Pacira sees 2026 total revenue of $735 mln to $760 mln, down from prior $745 mln to $770 mln
Company expects 2026 EXPAREL net product sales of $600 mln to $620 mln
Pacira forecasts 2026 non-GAAP gross margin of 77% to 79%

Result Drivers
EXAREL SALES - Q2 EXPAREL net product sales rose 3% year-over-year, with 4% volume growth partially offset by a shift in vial mix and expanded discount contracting programs related to group purchasing organizations
ZILRETTA SALES - ZILRETTA net product sales increased 4% year-over-year, contributing to overall revenue growth
LICENSE REVENUE - Sales of bupivacaine liposome injectable suspension to third-party licensees rose to $3.2 mln from $0.5 mln a year earlier

Company press release: ID:nGNX1swtYx

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Slight Beat*
$192.40 mln
$190.82 mln (5 Analysts)
Q2 Adjusted Net Income
Beat
$29.50 mln
$27.32 mln (4 Analysts)
Q2 Net Income
 
$4.70 mln
 
Q2 Adjusted EBITDA
Beat
$48.70 mln
$40.73 mln (3 Analysts)
Q2 Cash & Investments
 
$251 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Pacira Biosciences Inc is $28.50, about 5.9% above its August 3 closing price of $26.92
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 9 three months ago

Reuters Recommended Reads
Aug 3 - Supernus Q2 revenue rises on prescription volume; to merge with Indivior Pharma
Aug 3 - Ireland's Jazz Pharma Q2 revenue beats estimates on Zepzelca higher sales
Aug 4 - Harmony Biosciences Q2 WAKIX revenue beats on patient growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)